Lilemong tsa morao tjena, kalafo ea botenya le lefu la tsoekere la mofuta oa 2 e bile le tsoelo-pele ea phetoho. Ho latela li-agonists tsa GLP-1 (mohlala, Semaglutide) le li-agonists tse peli (mohlala, Tirzepatide),Retatrutide(LY3437943), aagonist e meraro(GLP-1, GIP, le li-receptor tsa glucagon), e bonts'itse katleho e neng e sa lebelloa. Ka liphello tse tsotehang tsa phokotso ea boima ba 'mele le ntlafatso ea metabolism, e nkoa e le phekolo e ka bang teng bakeng sa mafu a metabolic.
Mokhoa oa Ts'ebetso
-
Ts'ebetso ea li-receptor tsa GLP-1: E matlafatsa tlhahiso ea insulin, e kokobetsa takatso ea lijo, e liehisa ho tsoa ka mpeng.
-
Ts'ebetso ea receptor ea GIPE matlafatsa litlamorao tsa ho theola tsoekere ea GLP-1, e ntlafatsa kutloisiso ea insulin.
-
Ts'ebetso ea glucagon receptor: E khothaletsa tšebeliso ea matla le metabolism ea mafura.
Tšebelisano ea li-receptor tsena tse tharo e lumella Retatrutide ho feta lithethefatsi tse seng li ntse li le teng ho fokotsa boima ba 'mele le taolo ea glycemic.
Lintlha tsa Teko ea Kliniki (Mokhahlelo oa II)
Ho aTeko ea Phase II le bakuli ba 338 ba boima bo feteletseng / ba batenya, Retatrutide e bontšitse liphello tse tšepisang haholo.
Lethathamo: Papiso ea Retatrutide vs. Placebo
| Tekanyetso (mg/beke) | Ho Fokotsa Boima ba 'Mele (%) | Phokotso ea HbA1c (%) | Liketsahalo tse Tloaelehileng tse Mabe |
|---|---|---|---|
| 1 mg | -7.2% | -0.9% | Ho nyekeloa ke pelo, ho hlatsa ha bobebe |
| 4 mg | -12.9% | -1.5% | Nausea, tahlehelo ea takatso ea lijo |
| 8 mg | -17.3% | -2.0% | Ho se phutholohe ha GI, letšollo le bobebe |
| 12 mg | -24.2% | -2.2% | Ho nyekeloa ke pelo, ho lahleheloa ke takatso ea lijo, ho patoa |
| Sebaka | -2.1% | -0.2% | Ha ho phetoho e kholo |
Pono ea Boitsebiso (Papiso ea Phokotso ea Boima)
Chate e latelang ea bar e bontšaho fokotsa boima ba 'mele ka karolelanoho pholletsa le litekanyetso tse fapaneng tsa Retatrutide ha li bapisoa le placebo:
Nako ea poso: Sep-16-2025